<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432023000300948</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v6i18.276</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Importancia de los radiotrazadores MDP, DTPA, MIBI marcados con Tc99m en diagnóstico de medicina nuclear]]></article-title>
<article-title xml:lang="en"><![CDATA[Importance of Tc99m-labeled MDP, DTPA, MIBI radiotracers in nuclear medicine diagnostics]]></article-title>
<article-title xml:lang="pt"><![CDATA[Importância dos radiotraçadores MDP, DTPA e MIBI marcados com Tc99m em diagnósticos de medicina nuclear]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Paredes]]></surname>
<given-names><![CDATA[Kelly Muriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Juela]]></surname>
<given-names><![CDATA[Christian José Corte]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Católica de Cuenca  ]]></institution>
<addr-line><![CDATA[Cuenca ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>6</volume>
<numero>18</numero>
<fpage>948</fpage>
<lpage>960</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432023000300948&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432023000300948&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432023000300948&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La medicina nuclear utiliza radiofármacos, conocidos como radiotrazadores, para evaluar la función y el metabolismo de órganos y sistemas del cuerpo. Objetivo. Examinar la relevancia de los radiotrazadores MDP, DTPA y MIBI, marcados con tecnecio-99m (Tc99m), en el diagnóstico en medicina nuclear. Metodología. Se siguió el método PRISMA para identificar estudios publicados entre 2010 y 2022. Las bases de datos consultadas incluyeron Dialnet, Elsevier, Research, Redalyc, PubMed, Google Académico y Scielo. Se utilizaron descriptores específicos como "radiotrazadores Tc99m", "MDP", "DTPA", "MIBI", y "medicina nuclear", centrando la búsqueda en diagnóstico y excluyendo propósitos terapéuticos. Resultados. De 14 estudios analizados, se observó una predominancia en investigaciones sobre radiotrazadores MDP y MIBI marcados con Tc99m, enfocándose en diagnósticos relacionados con lesiones paratiroideas, hiperparatiroidismo, enfermedades esqueléticas, enfermedad arterial coronaria y perfusión miocárdica. Conclusiones. Los radiotrazadores MDP, DTPA y MIBI marcados con Tc99m demuestran eficacia en diversas aplicaciones diagnósticas, incluyendo la localización de adenomas paratiroideos y la detección de condiciones como el mieloma múltiple. A pesar de sus beneficios, es crucial continuar investigando y desarrollando nuevos radiofármacos para expandir su utilidad clínica y mejorar aún más la atención médica en el campo de la medicina nuclear.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Nuclear medicine uses radiopharmaceuticals, known as radiotracers, to assess the function and metabolism of organs and body systems. Objective. To examine the relevance of technetium-99m (Tc99m)-labeled MDP, DTPA, and MIBI radiotracers in nuclear medicine diagnostics. Methodology. The PRISMA method was followed to identify studies published between 2010 and 2022. The databases consulted included Dialnet, Elsevier, Research, Redalyc, PubMed, Google Scholar and Scielo. Specific descriptors such as "Tc99m radiotracers", "MDP", "DTPA", "MIBI", and "nuclear medicine" were used, focusing the search on diagnosis and excluding therapeutic purposes. Results. Of 14 studies analyzed, there was a predominance of research on Tc99m-labeled MDP and MIBI radiotracers, focusing on diagnoses related to parathyroid lesions, hyperparathyroidism, skeletal diseases, coronary artery disease, and myocardial perfusion. Conclusions. Tc99m-labeled MDP, DTPA, and MIBI radiotracers demonstrate efficacy in a variety of diagnostic applications, including localization of parathyroid adenomas and detection of conditions such as multiple myeloma. Despite their benefits, it is crucial to continue researching and developing new radiopharmaceuticals to expand their clinical utility and further improve medical care in the field of nuclear medicine.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO A medicina nuclear utiliza radiofármacos, conhecidos como radiotraçadores, para avaliar a função e o metabolismo de órgãos e sistemas corporais. Objetivo. Examinar a importância dos radiotraçadores MDP, DTPA e MIBI, marcados com tecnécio-99m (Tc99m), em diagnósticos de medicina nuclear. Metodologia. O método PRISMA foi usado para identificar estudos publicados entre 2010 e 2022. Os bancos de dados consultados incluíram Dialnet, Elsevier, Research, Redalyc, PubMed, Google Scholar e Scielo. Foram utilizados descritores específicos como "radiotraçadores Tc99m", "MDP", "DTPA", "MIBI" e "medicina nuclear", concentrando a busca em fins diagnósticos e excluindo fins terapêuticos. Resultados. Dos 14 estudos analisados, houve predomínio de pesquisas com os radiotraçadores MDP e MIBI marcados com Tc99m, com foco em diagnósticos relacionados a lesões da paratireoide, hiperparatireoidismo, doenças esqueléticas, doença arterial coronariana e perfusão miocárdica. Conclusões. Os radiotraçadores MDP, DTPA e MIBI marcados com Tc99m demonstram eficácia em uma variedade de aplicações diagnósticas, incluindo a localização de adenomas de paratireoide e a detecção de doenças como o mieloma múltiplo. Apesar de seus benefícios, é fundamental continuar a pesquisa e o desenvolvimento de novos radiofármacos para expandir sua utilidade clínica e melhorar ainda mais o atendimento médico no campo da medicina nuclear.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Medronato de Tecnecio Tc 99m]]></kwd>
<kwd lng="es"><![CDATA[Pentetato de Tecnecio Tc 99m]]></kwd>
<kwd lng="es"><![CDATA[Tecnecio Tc 99m Sestamibi]]></kwd>
<kwd lng="en"><![CDATA[Technetium Tc 99m Medronate]]></kwd>
<kwd lng="en"><![CDATA[Technetium Tc 99m Pentetate]]></kwd>
<kwd lng="en"><![CDATA[Technetium Tc 99m Sestamibi]]></kwd>
<kwd lng="pt"><![CDATA[Medronato de Tecnécio Tc 99m]]></kwd>
<kwd lng="pt"><![CDATA[Pentetato de Tecnécio Tc 99m]]></kwd>
<kwd lng="pt"><![CDATA[Tecnécio Tc 99m Sestamibi]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aplicaciones médicas de los aceleradores de partículas]]></article-title>
<source><![CDATA[Tesis]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofármacos de uso humano: marco legal e indicaciones clínicas autorizadas en España]]></article-title>
<source><![CDATA[Seguridad Nuclear]]></source>
<year>2003</year>
<page-range>5-15</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chain]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Illanes]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofármacos en medicina nuclear]]></article-title>
<source><![CDATA[Series: Libros de Cátedra]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faria]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Buchpiguel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Marques]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alternative chromatographic system for the quality control of lipophilic technetium-99m radiopharmaceuticals such as 99mTc(MIBI)6+]]></article-title>
<source><![CDATA[Brazilian Journal of Medical and Biological Research]]></source>
<year>2015</year>
<volume>48</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>902-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Agentes de diagnóstico y radiofarmacia]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2002</year>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aréstegui]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control de calidad mediante cromatografía en el radiofármaco Tc 99m-MDP en el Centro Avanzado de Medicina Nuclear PETSCAN]]></article-title>
<source><![CDATA[Tesis]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estrada]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preparation and stability of the Tc-HNE radiopharmaceutical; Preparacion y estabilidad del radiofarmaco TC-HNE]]></article-title>
<source><![CDATA[Tesis]]></source>
<year>2002</year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas]]></article-title>
<source><![CDATA[Revista española de cardiología]]></source>
<year>2021</year>
<volume>74</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>790-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of ultrasonography and Tc-99m MIBI SPECT/CT in preoperative localization of parathyroid adenomas causing primary hyperthyroidism]]></article-title>
<source><![CDATA[BMC medical imaging]]></source>
<year>2021</year>
<page-range>1-87</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mir]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extraosseous soft tissue uptake-in Multiple Myeloma]]></article-title>
<source><![CDATA[The Journal of the Pakistan Medical Association]]></source>
<year>2022</year>
<volume>72</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1454-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quak]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Upfront F18-choline PET/CT versus Tc99m-sestaMIBI SPECT/CT guided surgery in primary hyperparathyroidism: the randomized phase III diagnostic trial APACH2]]></article-title>
<source><![CDATA[BMC]]></source>
<year>2021</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dheer]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimization of Ordered Subset Expectation Maximization Parameters for Image Reconstruction in Tc-99m Methoxyisobutylisonitrile Myocardial Perfusion SPECT and Comparison with Corresponding Filtered Back Projection-Reconstructed Image.]]></article-title>
<source><![CDATA[Indian journal of nuclear medicine: IJNM: the official journal of the Society of Nuclear Medicine]]></source>
<year>2021</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-20</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A preoperative parathyroid scan is important for the total removal of the transplanted parathyroid tissue in recurrent secondary hyperthyroidism: A case report and literature review]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2022</year>
<volume>101</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[BT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential findings of tc-99m sestamibi dual-phase parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism]]></article-title>
<source><![CDATA[Nucl Med Mol Imaging.]]></source>
<year>2011</year>
<volume>45</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kilambi]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of Epicardial Fat Volume between Patients with Normal Perfusion and Reversible Perfusion Abnormalities on Myocardial Perfusion Imaging]]></article-title>
<source><![CDATA[Indian journal of nuclear medicine: IJNM: the official journal of the Society of Nuclear Medicine]]></source>
<year>2021</year>
<volume>36</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García San Miguel]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update of the role of Nuclear Medicine techniques in the pre-surgical localization of primary hyperparathyroidism]]></article-title>
<source><![CDATA[Revista Española de Medicina Nuclear e Imagen Molecular]]></source>
<year>2019</year>
<volume>38</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>123-35</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Reacción adversa al Tc-oxidronato tras reexposición al radiofármaco]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reacciones adversas a radiofármacos]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of technetium 99 metastable radioactive Nanosystems: nanoparticles, liposomes, and Nanoemulsion for biomedical application]]></article-title>
<source><![CDATA[Current Pharmacology Reports]]></source>
<year>2019</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>281-302</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsopelas]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotracers used for the scintigraphic detection of infection and inflammation.]]></article-title>
<source><![CDATA[The Scientific World Journal]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miko&#322;ajczak]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiopharmaceuticals in cardiology]]></article-title>
<source><![CDATA[Nuclear Medicine Review]]></source>
<year>2012</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-45</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gibson]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of Tc-99m-DTPA nuclear medicine GFR studies in pediatric solid tumor patients]]></article-title>
<source><![CDATA[Journal of Pediatric Hematology/Oncology]]></source>
<year>2013</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ulloa]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión de los principios básicos de medicina nuclear y radiofarmacia.]]></article-title>
<source><![CDATA[Rev Col Microb Quim Cli Costa Rica]]></source>
<year>2018</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
